A carregar...
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
As a result of the anti-tumour activity observed in vitro and in vivo with combined anti-CD20 and anti-CD74 antibodies, we initiated a phase I/II trial of veltuzumab and milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). Patients received an induction of veltuzuma...
Na minha lista:
| Publicado no: | Br J Haematol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7297055/ https://ncbi.nlm.nih.gov/pubmed/25847298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.13354 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|